Literature DB >> 7131143

Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport.

L J Waber, D Valle, C Neill, S DiMauro, A Shug.   

Abstract

We studied a boy who presented at age 3 1/2 years with cardiomegaly, a distinctive electrocardiogram, and a history of a brother dying with cardiomyopathy. From age 3 1/2 to 5 years, cardiac disease progressed, resulting in intractable congestive heart failure. Skeletal muscle weakness developed and a muscle biopsy showed lipid myopathy. Muscle and plasma carnitine were reduced to 2 and 10% of the normal mean values, respectively. Therapy with L-carnitine (174 mg/kg/da) was begun at age 5 1/2 years and continued to the present (age 6 1/2 years). The cardiac disease has resolved and the muscle strength has returned to normal. Plasma carnitine concentrations have risen to the low-normal range, while urinary carnitine excretion has increased to values which are 30 times normal. The renal clearance of carnitine exceeds normal at all plasma concentrations and plasma carnitine values do not change acutely after an oral carnitine load. These results suggest that there is a distinct form of carnitine deficiency which presents as cardiomyopathy and may be successfully treated with L-carnitine. A defect in renal and possibly gastrointestinal transport of carnitine is a likely cause of this patient's disorder.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7131143     DOI: 10.1016/s0022-3476(82)80294-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  42 in total

1.  Carnitine deficiency with cardiomyopathy presenting as neonatal hydrops: successful response to carnitine therapy.

Authors:  P Steenhout; C Elmer; A Clercx; D Blum; D Gnat; S van Erum; F Vertongen; E Vamos
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

Review 2.  L-Carnitine.

Authors:  J H Walter
Journal:  Arch Dis Child       Date:  1996-06       Impact factor: 3.791

Review 3.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

4.  Familial restrictive cardiomyopathy with atrioventricular block and skeletal myopathy.

Authors:  A P Fitzpatrick; L M Shapiro; A F Rickards; P A Poole-Wilson
Journal:  Br Heart J       Date:  1990-02

Review 5.  Matrix revisited: mechanisms linking energy substrate metabolism to the function of the heart.

Authors:  Andrew N Carley; Heinrich Taegtmeyer; E Douglas Lewandowski
Journal:  Circ Res       Date:  2014-02-14       Impact factor: 17.367

6.  The myocardial distribution and plasma concentration of carnitine in patients with mitral valve disease.

Authors:  T Nakagawa; M Sunamori; A Suzuki
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

7.  Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies.

Authors:  Sook Wah Yee; Dina Buitrago; Adrian Stecula; Huy X Ngo; Huan-Chieh Chien; Ling Zou; Megan L Koleske; Kathleen M Giacomini
Journal:  FASEB J       Date:  2020-10-30       Impact factor: 5.191

8.  Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes. Evidence for alterations in tissue carnitine transport.

Authors:  C J Rebouche; A G Engel
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

9.  Carnitine metabolism and inborn errors.

Authors:  A G Engel; C J Rebouche
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

Review 10.  l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism.

Authors:  K L Goa; R N Brogden
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.